Doxorubicin is a chemotherapy medication used to treat cancer. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer, so that more of the drug reaches the cancer cells. Doxorubicin includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia and is given by injection into a vein.
MARKET DYNAMICS
The liposomal doxorubicin market is anticipated to owing to the growing availability of the product. However, some side-effects associated with Liposomal Doxorubicin is expected to hinder the growth of the market over the forecast period. Moreover, the increasing involvement of significant private players to reduce redundancies and complexities in the global supply chain is expected to benefit the growth of the market in the forecast period.
MARKET SCOPE
The "Liposomal Doxorubicin Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of in liposomal doxorubicin market with detailed market segmentation by product type, application and geography. The liposomal doxorubicin market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading in liposomal doxorubicin market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The liposomal doxorubicin market is segmented on the basis of product type and application. Based on product type the market is segmented as J&J (doxil/caelyx), sun pharma (lipodox), teva (myocet) and others. On the basis of application the market is categorized bone sarcoma, breast cancer, endometrial cancer, gastric cancer, kaposi sarcoma, kidney cancer, leukemia, liver cancer, multiple myeloma, other applications and ovarian cancer.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in liposomal doxorubicin market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The liposomal doxorubicin market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting liposomal doxorubicin market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the liposomal doxorubicin market in these regions.
Have a question?
Akshay
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in liposomal doxorubicin market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The liposomal doxorubicin market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting liposomal doxorubicin market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the liposomal doxorubicin market in these regions.
MARKET PLAYERS
The report covers key developments in the in liposomal doxorubicin market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from in liposomal doxorubicin market are anticipated to have lucrative growth opportunities in the future with the rising demand for in liposomal doxorubicin market in the global market. Below mentioned is the list of few companies engaged in the liposomal doxorubicin market.
The report also includes the profiles of key in liposomal doxorubicin market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Cadila Pharmaceuticals
- Cipla, Inc.
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- Merck & Co.
- Pfizer Inc.
- Sanofi
- Sigma-Aldrich Co.
- SRS Pharmaceuticals Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Liposomal Doxorubicin Market - By Product Type
1.3.2 Liposomal Doxorubicin Market - By Application
1.3.3 Liposomal Doxorubicin Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LIPOSOMAL DOXORUBICIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LIPOSOMAL DOXORUBICIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. LIPOSOMAL DOXORUBICIN MARKET - GLOBAL MARKET ANALYSIS
6.1. LIPOSOMAL DOXORUBICIN - GLOBAL MARKET OVERVIEW
6.2. LIPOSOMAL DOXORUBICIN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. LIPOSOMAL DOXORUBICIN MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. JANDJ (DOXIL/CAELYX)
7.3.1. Overview
7.3.2. JandJ (Doxil/Caelyx) Market Forecast and Analysis
7.4. SUN PHARMA (LIPODOX)
7.4.1. Overview
7.4.2. Sun Pharma (Lipodox) Market Forecast and Analysis
7.5. TEVA (MYOCET)
7.5.1. Overview
7.5.2. Teva (Myocet) Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. LIPOSOMAL DOXORUBICIN MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. BONE SARCOMA
8.3.1. Overview
8.3.2. Bone Sarcoma Market Forecast and Analysis
8.4. BREAST CANCER
8.4.1. Overview
8.4.2. Breast Cancer Market Forecast and Analysis
8.5. ENDOMETRIAL CANCER
8.5.1. Overview
8.5.2. Endometrial Cancer Market Forecast and Analysis
8.6. GASTRIC CANCER
8.6.1. Overview
8.6.2. Gastric Cancer Market Forecast and Analysis
8.7. KAPOSI SARCOMA
8.7.1. Overview
8.7.2. Kaposi Sarcoma Market Forecast and Analysis
8.8. KIDNEY CANCER
8.8.1. Overview
8.8.2. Kidney Cancer Market Forecast and Analysis
8.9. LEUKEMIA
8.9.1. Overview
8.9.2. Leukemia Market Forecast and Analysis
8.10. LIVER CANCER
8.10.1. Overview
8.10.2. Liver Cancer Market Forecast and Analysis
8.11. MULTIPLE MYELOMA
8.11.1. Overview
8.11.2. Multiple Myeloma Market Forecast and Analysis
8.12. OTHER APPLICATIONS
8.12.1. Overview
8.12.2. Other Applications Market Forecast and Analysis
8.13. OVARIAN CANCER
8.13.1. Overview
8.13.2. Ovarian Cancer Market Forecast and Analysis
9. LIPOSOMAL DOXORUBICIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Liposomal Doxorubicin Market Overview
9.1.2 North America Liposomal Doxorubicin Market Forecasts and Analysis
9.1.3 North America Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.1.4 North America Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.1.5 North America Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.1.5.1 United States Liposomal Doxorubicin Market
9.1.5.1.1 United States Liposomal Doxorubicin Market by Product Type
9.1.5.1.2 United States Liposomal Doxorubicin Market by Application
9.1.5.2 Canada Liposomal Doxorubicin Market
9.1.5.2.1 Canada Liposomal Doxorubicin Market by Product Type
9.1.5.2.2 Canada Liposomal Doxorubicin Market by Application
9.1.5.3 Mexico Liposomal Doxorubicin Market
9.1.5.3.1 Mexico Liposomal Doxorubicin Market by Product Type
9.1.5.3.2 Mexico Liposomal Doxorubicin Market by Application
9.2. EUROPE
9.2.1 Europe Liposomal Doxorubicin Market Overview
9.2.2 Europe Liposomal Doxorubicin Market Forecasts and Analysis
9.2.3 Europe Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.2.4 Europe Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.2.5 Europe Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Liposomal Doxorubicin Market
9.2.5.1.1 Germany Liposomal Doxorubicin Market by Product Type
9.2.5.1.2 Germany Liposomal Doxorubicin Market by Application
9.2.5.2 France Liposomal Doxorubicin Market
9.2.5.2.1 France Liposomal Doxorubicin Market by Product Type
9.2.5.2.2 France Liposomal Doxorubicin Market by Application
9.2.5.3 Italy Liposomal Doxorubicin Market
9.2.5.3.1 Italy Liposomal Doxorubicin Market by Product Type
9.2.5.3.2 Italy Liposomal Doxorubicin Market by Application
9.2.5.4 Spain Liposomal Doxorubicin Market
9.2.5.4.1 Spain Liposomal Doxorubicin Market by Product Type
9.2.5.4.2 Spain Liposomal Doxorubicin Market by Application
9.2.5.5 United Kingdom Liposomal Doxorubicin Market
9.2.5.5.1 United Kingdom Liposomal Doxorubicin Market by Product Type
9.2.5.5.2 United Kingdom Liposomal Doxorubicin Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Liposomal Doxorubicin Market Overview
9.3.2 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis
9.3.3 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.3.4 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Liposomal Doxorubicin Market
9.3.5.1.1 Australia Liposomal Doxorubicin Market by Product Type
9.3.5.1.2 Australia Liposomal Doxorubicin Market by Application
9.3.5.2 China Liposomal Doxorubicin Market
9.3.5.2.1 China Liposomal Doxorubicin Market by Product Type
9.3.5.2.2 China Liposomal Doxorubicin Market by Application
9.3.5.3 India Liposomal Doxorubicin Market
9.3.5.3.1 India Liposomal Doxorubicin Market by Product Type
9.3.5.3.2 India Liposomal Doxorubicin Market by Application
9.3.5.4 Japan Liposomal Doxorubicin Market
9.3.5.4.1 Japan Liposomal Doxorubicin Market by Product Type
9.3.5.4.2 Japan Liposomal Doxorubicin Market by Application
9.3.5.5 South Korea Liposomal Doxorubicin Market
9.3.5.5.1 South Korea Liposomal Doxorubicin Market by Product Type
9.3.5.5.2 South Korea Liposomal Doxorubicin Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Liposomal Doxorubicin Market Overview
9.4.2 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis
9.4.3 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.4.4 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Liposomal Doxorubicin Market
9.4.5.1.1 South Africa Liposomal Doxorubicin Market by Product Type
9.4.5.1.2 South Africa Liposomal Doxorubicin Market by Application
9.4.5.2 Saudi Arabia Liposomal Doxorubicin Market
9.4.5.2.1 Saudi Arabia Liposomal Doxorubicin Market by Product Type
9.4.5.2.2 Saudi Arabia Liposomal Doxorubicin Market by Application
9.4.5.3 U.A.E Liposomal Doxorubicin Market
9.4.5.3.1 U.A.E Liposomal Doxorubicin Market by Product Type
9.4.5.3.2 U.A.E Liposomal Doxorubicin Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Liposomal Doxorubicin Market Overview
9.5.2 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis
9.5.3 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.5.4 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.5.5 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Liposomal Doxorubicin Market
9.5.5.1.1 Brazil Liposomal Doxorubicin Market by Product Type
9.5.5.1.2 Brazil Liposomal Doxorubicin Market by Application
9.5.5.2 Argentina Liposomal Doxorubicin Market
9.5.5.2.1 Argentina Liposomal Doxorubicin Market by Product Type
9.5.5.2.2 Argentina Liposomal Doxorubicin Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LIPOSOMAL DOXORUBICIN MARKET, KEY COMPANY PROFILES
11.1. CADILA PHARMACEUTICALS
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. CIPLA, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. GLAXOSMITHKLINE PLC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. JOHNSON AND JOHNSON SERVICES, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MERCK AND CO.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. PFIZER INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. SANOFI
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SIGMA-ALDRICH CO.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SRS PHARMACEUTICALS PVT. LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Cadila Pharmaceuticals
2. Cipla, Inc.
3. GlaxoSmithKline plc.
4. Johnson & Johnson Services, Inc.
5. Merck & Co.
6. Pfizer Inc.
7. Sanofi
8. Sigma-Aldrich Co.
9. SRS Pharmaceuticals Pvt. Ltd.
10. Sun Pharmaceutical Industries Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Liposomal Doxorubicin Market
Apr 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Apr 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Apr 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)